Everything tagged "nasdaq" across the TickerSpark archives.
D-Wave Quantum Inc. (NASDAQ: QBTS) is expected to list on 2026-07-27, but the price range has not been disclosed. The setup is a bull case built on rapid revenue growth and a large cash balance, versus a bear case centered on dilution, losses, and a still-early quantum market.
Instinct Bio Technical Co. Holdings Inc. (BIOT) is expected to list on NASDAQ on 2026-07-24, but the price range has not been disclosed. This is a SPAC business combination, not a traditional underwritten IPO. The bull case is a vertically integrated regenerative medicine and stem-cell skincare platform; the bear case is that the public story is still light on disclosed financial detail.
Pelican Acquisition Ii Corp. (NASDAQ: PLCIU) is expected to list on 2026-07-24, but the price range has not been disclosed yet. The SPAC is offering 7,500,000 shares with a $75,000,000 market cap if disclosed terms hold. Bull case: a clean trust-backed structure and experienced sponsor team; bear case: no operating business yet and no target announced.
InterPrivate Investment Partners V, Inc. Class A Ordinary Shares (NASDAQ: IPVV) is expected to list on 2026-07-27. The price range has not been disclosed yet. The bull case is sponsor execution in a reopening SPAC market; the bear case is the usual blank-check uncertainty until a target is found.
Biotech Acquisition Company is expected to list on NASDAQ on 2026-07-24, but the price range has not been disclosed yet. This is a SPAC, so the real story is not current revenue — it is whether the sponsor can find and close a healthcare or biotech deal that the market will back. The setup favors target-selection upside, but shareholders should watch the trust structure, redemption risk, and the lack of operating business today.
ProShares Ultra QQQ Equal Weight (NASDAQ: EQQQ) is expected to list on 2026-07-23, but the price range has not been disclosed. This is a leveraged ETF launch, not a traditional operating-company IPO, so the key question is whether investors want 2x daily exposure to an equal-weight Nasdaq-100 strategy. The bull case is differentiated tech exposure; the bear case is the usual leveraged-ETF volatility and path dependence.
CAE Inc. is expected to list on NASDAQ on 2026-07-23, but the price range has not been disclosed. The key question is not valuation yet — it is whether this is truly a new IPO, because the company’s filings and investor materials show CAE is already a long-public issuer. Watch for confirmation of the listing structure, since the setup currently looks more like a data mismatch than a fresh offering.
Hotchkis & Wiley Opportunities Fund is expected to list on NASDAQ on 2026-07-22, but the price range has not been disclosed. This is not a classic operating-company IPO; it is an ETF share-class registration for an existing active value fund. The setup favors investors who want a seasoned value manager, but shareholders should watch ETF trading dynamics and any discount to NAV.
Hotchkis & Wiley International Value Fund is expected to list on NASDAQ on 2026-07-22, but the price range has not been disclosed. The key question is whether investors want an established international value fund platform as it adds an ETF share class. The setup favors a steady, research-driven strategy, but foreign-market, currency, and emerging-markets risk remain central.
Scribe Therapeutics, Inc. (NASDAQ: SCTX) is expected to list on 2026-07-24 at a price range of $13.00 to $15.00 per share. The company is offering 7,150,000 shares, with a disclosed market cap of $123,337,500. The bull case is a differentiated CRISPR platform aimed at cardiometabolic disease; the bear case is an early-stage story with no approved products and substantial going-concern risk.
Freenome, Inc. Common stock (NASDAQ: FRNM) is expected to list on 2026-07-21, but the price range has not been disclosed yet. The company is going public through a SPAC merger with Perceptive Capital Solutions Corp., not a traditional IPO. Bulls will focus on the 2026 launch plan and large healthcare-investor PIPE; bears will focus on heavy losses and a still-unproven commercialization path.
Cue Health Inc. (NASDAQ: HLTH) is expected to list on 2026-07-21 in a priced deal with a $15 to $17 range. The company is pitching connected diagnostics and at-home testing, but shareholders should watch how much of the story still depends on testing demand and regulatory execution.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime